BOC-D-leucine (CAS 16937-99-8; synonym N-tert-butoxycarbonyl-D-leucine) is the protected D-enantiomer of leucine in which the α-amine is blocked by a tert-butoxycarbonyl group. The anhydrous form has molecular formula C₁₁H₂₁NO₄, molecular weight 231.29 g/mol, and monoisotopic mass 231.1471 Da; monohydrate lots carry one lattice water and have a formula weight of 249.31 g/mol. The BOC protecting group adds 100.12 Da to the free D-leucine mass of 131.17 g/mol. The product is supplied as a white to off-white crystalline powder, and the principal commercial forms are a research reagent grade with HPLC purity ≥98.0% and a pharmaceutical intermediate grade with HPLC purity ≥99.0% and enantiomeric purity ≥99.0%. No formal ISO or DIN model designation applies to this fine chemical; users specify the material through CAS registry, enantiomeric excess, water content, residual solvent profile, and specific rotation. Typical release methods include Karl Fischer titration (USP 921 / Ph. Eur. 2.5.12), gas chromatographic residual solvent testing (USP 467 / Ph. Eur. 5.4), and polarimetric measurement (USP 781 / Ph. Eur. 2.2.7). The tert-butoxycarbonyl group blocks the α-amine and leaves the carboxylic acid available for selective activation; the D-configuration at the α-carbon is retained through coupling and changes the stereochemical and proteolytic recognition profile of downstream peptide chains.

What Limits the Acid-Lability Window of the tert-Butoxycarbonyl Group in D-Leucine Derivatives?

Acidolysis of BOC-D-leucine is typically performed in dichloromethane with trifluoroacetic acid at volumetric ratios of 1:1 to 1:4 at 20 °C. The free α-amine is liberated within 15–30 min under these conditions as determined by C18 HPLC using a 0.1% TFA/acetonitrile gradient and detection at 210 nm. Added water (2.5–5.0% v/v) and triisopropylsilane (1.0–2.5% v/v) scavenge the tert-butyl cation. Anhydrous TFA and temperatures above 30 °C promote tert-butyl esterification at the carboxyl terminus and produce leucine tert-butyl ester impurities that are difficult to separate from the desired peptide by normal-phase chromatography.

In solid-phase synthesis, the deprotection rate on polystyrene-divinylbenzene resin depends on resin swelling and solvent diffusion. Resins with 1–2% divinylbenzene cross-linking swell adequately in dichloromethane, and the apparent first-order half-life for α-BOC removal is below 3 min at 20 °C in well-solvated beads; however, the full cycle is extended to 15–30 min to accommodate diffusion through collapsed pores near the bead core. After acidolysis, the intermediate exists as a trifluoroacetate salt. The salt is neutralized with 5% N,N-diisopropylethylamine in DMF before the next coupling. If residual acid is not fully removed, the next amide coupling yield declines by 2–5% per cycle, as measured by quantitative ninhydrin or by Fmoc release following a control coupling. Automated synthesizers are programmed with a rinse volume of 8–10 mL of DMF per gram of resin to displace the acid salt.

The side chain of D-leucine is an isobutyl group and does not require side-chain scavenger protection during acidolysis. This reduces the scavenger burden relative to methionine- or tryptophan-containing sequences. However, the process boundary remains narrow above 25 °C; jacketed reactor systems are held at 20–25 °C, and deprotection is quenched by evaporation or precipitation before any aqueous workup to avoid re-carbamate formation or ester hydrolysis. Published kinetic data for resin-bound BOC-D-leucine under pilot-scale peptide synthesizer conditions are limited; the values above are representative of standard laboratory-grade reagents and single-bead studies.

Enantiomeric purity is not established by achiral HPLC because D- and L-BOC-leucine coelute on standard C18 columns. A normal-phase chiral HPLC method using an amylose tris(3,5-dimethylphenylcarbamate) stationary phase resolves BOC-D-leucine from BOC-L-leucine in n-hexane/2-propanol containing 0.1% trifluoroacetic acid; on a 250 × 4.6 mm column the 2-propanol fraction is adjusted within 3–10% to hold resolution at or above 1.5. Detection at 210 nm provides sufficient carbonyl absorbance, but baseline noise increases if the trifluoroacetic acid fraction exceeds 0.1%. Column temperature is controlled at 25 °C; retention drift greater than 0.2 min across six injections indicates that the mobile phase requires replacement or that water has entered the solvent reservoir. Optical rotation is used as an orthogonal identity test: BOC-D-leucine shows positive rotation in methanol, while BOC-L-leucine shows negative rotation under identical conditions. A batch of BOC-D-leucine with specific rotation outside +24.0° to +26.0° at 20 °C and c = 1 is held for chiral HPLC before release. Because the compound can retain crystallization solvent, residual solvent testing by headspace gas chromatography is conducted in parallel with Karl Fischer titration. The following release profile is representative for an anhydrous pharmaceutical intermediate grade.

Comparative Orthogonality Against Cbz and Fmoc Protection Strategies

BOC-D-leucine is distinguished from Fmoc-D-leucine and Cbz-D-leucine by the conditions used for N-amine release and by the analytical by-products generated during deprotection. BOC-D-leucine is stable to catalytic hydrogenolysis and to 20% piperidine in DMF for at least 2 h at 20 °C, but is cleaved by 1:1 TFA/DCM within 15–30 min. Fmoc-D-leucine is removed by 20% piperidine in DMF within 15–20 min and remains intact under the TFA conditions used to deprotect side-chain BOC groups. The Fmoc deprotection generates a dibenzylfulvene-piperidine adduct that absorbs at 301 nm, enabling direct UV-based quantitation in automated peptide synthesizers; BOC-D-leucine has no comparable chromophoric release product, so deprotection is monitored by ninhydrin, free-amine HPLC, or subsequent coupling test. Cbz-D-leucine is removed by hydrogen gas at 1–3 atm over palladium on carbon or by 33% hydrogen bromide in acetic acid; it is stable to both piperidine and TFA, which makes it useful in routes where acid and base lability must be minimized. Molecular weight and typical activation conditions differ as shown in the matrix below.

For route design, the choice of BOC-D-leucine versus Fmoc-D-leucine is not simply a substitution of one reagent for another: Fmoc-D-leucine has molecular weight 353.41 g/mol, so the mass loaded per mole is higher, and its deprotection is monitored by UV at 301 nm. BOC-D-leucine has molecular weight 231.29 g/mol and is preferred when the target sequence tolerates repeated TFA deprotection but must remain stable to piperidine or hydrogenation. When orthogonal protection is needed at two amine positions in the same fragment, BOC-D-leucine and Cbz-D-leucine may be used together, with Cbz removed by hydrogenolysis and BOC retained, then BOC removed by TFA. The compatibility of BOC-D-leucine with catalytic hydrogenation is a key operational distinction from Cbz-D-leucine in routes where the peptide backbone contains no other hydrogenation-sensitive functionality.

On multi-kilogram peptide API campaigns, BOC-D-leucine is introduced as a solid into a glass-lined or Hastelloy C-22 reactor under a nitrogen stream. The reactor jacket is maintained at 20–25 °C during dissolution in DMF or dichloromethane and is not allowed to exceed 35 °C because hot solvent accelerates carbamate solvolysis and can generate free D-leucine. Solid material left open at 60% relative humidity for more than 4 h may exceed the water limit; production suites therefore pre-dry the material under vacuum at 25–30 °C when received water content is out of specification, and material is dispensed through flexible intermediate bulk containers with desiccant cartridges. The compound is incompatible with strong acids such as TFA and HCl in dioxane except in intentional deprotection, and it is not stored in the presence of hot aqueous alkali, which hydrolyzes the carbamate to the parent amino acid.

After solution-phase coupling, the urea by-product from carbodiimide reagents is removed by filtration through a 0.45 µm polypropylene filter before precipitation from ethyl acetate/n-heptane. Unreacted free D-leucine and free amine-containing impurities are monitored by HILIC or by a free-amine derivatization method because direct HPLC area percent at 210 nm under-reports the zwitterionic free amino acid. Batch-to-batch variance in specific rotation across 25 kg production lots is typically held within ±0.3° when drying and dispensing are controlled; out-of-trend rotation triggers chiral HPLC and Karl Fischer re-test prior to use. These controls are required because the protected monomer is the terminal building block in sequences where a single D-residue controls biological activity and where enantiomeric contamination cannot be removed by downstream recrystallization.

When BOC-D-Leucine Replaces Free D-Leucine in Solution-Phase Amide Bond Formation

Replacing free D-leucine with BOC-D-leucine in solution-phase amide bond formation changes the solubility profile, the activation chemistry, and the molecular weight basis for charging. Free D-leucine is a zwitterion with limited solubility in chlorinated and aromatic solvents; it requires tertiary base or water to dissolve and generates an ammonium carboxylate that can interfere with carbodiimide activation. BOC-D-leucine dissolves directly in dichloromethane, tetrahydrofuran, and DMF at concentrations up to 0.5 M at 20 °C, and the protected carboxyl group can be activated with DIC/HOBt or EDC/HOBt without competing acylation at the α-amine. This selectivity reduces diketopiperazine-related ring closure and urea side products in hindered ester couplings.

The molecular weight shift from 131.17 g/mol for free D-leucine to 231.29 g/mol for BOC-D-leucine changes reagent mass calculations. A 1.0 mol reaction in a 50 L reactor requires 231.3 g of the protected derivative instead of 131.2 g of free D-leucine. The additional organic solvent capacity is offset by the removal of aqueous workup for free amino acid salt extraction. After coupling, the BOC group is removed quantitatively with TFA/DCM; the mass of the protecting group is accounted for in the isolated peptide mass balance. The D-configuration is retained through coupling under carbodiimide conditions when the reaction is kept below 5 °C; racemization of BOC-protected amino acids is generally lower than that of free zwitterionic amino acids, but enantiomeric purity of the resulting peptide is confirmed by chiral HPLC after deprotection.

In peptide sequences where D-leucine is included to restrict aminopeptidase recognition, BOC-D-leucine is introduced at the same coupling cycle as L-amino acids. Published degradation data for model dipeptides under leucine aminopeptidase exposure indicate that D-Leu substitution can reduce hydrolysis rates, but specific half-life values for a given BOC-D-leucine-derived sequence are limited and must be determined in the target peptide stability assay. BOC-D-leucine is therefore classified as a chiral building block rather than a general stabilizer. Operational boundaries include the need to exclude moisture during storage, avoid accidental strong-acid contact, and prevent heating above 35 °C in protic solvent because the carbamate linkage is thermally and chemically labile.